As various types of NRP1 blockade can modulate multiple signaling pathways of proangiogenic growth factors, this approach has also been expected to increase antitumor efficacy of some antiangiogenic agents by making tumor vessels vulnerable to anti-VEGF therapy [13,15]. The gene discussed is VEGFA; the disease is neoplasm.